Document:

Exhibit 10.20

 Exhibit 10.20 
 ESCROW AGREEMENT 
 This Escrow Agreement is made and
entered into as of the     th
day of             , 2010, by and among ANDERSON & STRUDWICK, INCORPORATED, a Virginia corporation (the “Placement Agent”), TIBET PHARMACEUTICALS, INC., a British
Virgin Islands company (the “Company”) and SUNTRUST BANK (the “Escrow Agent”). 
 R E C I T A L S:

 A. The Company proposes to sell a minimum of 2,500,000 common shares and a maximum of 3,000,000 common shares (the
“Shares”) of the Company at a price of $         per share on a “best efforts, minimum/maximum” basis (the “Offering”). 

B. The Company has retained the Placement Agent, as agent for the Company to sell the Shares in the Offering, and the Placement Agent has
agreed to sell the shares in the Offering as the Company’s agent. 
 C. The Escrow Agent is willing to hold the proceeds of
the Offering in escrow pursuant to this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing and the mutual covenants
and agreements contained in this Agreement, it is hereby agreed as follows: 
 1. Establishment of the Escrow Agent.
Contemporaneously herewith, the parties have established a non-interest-bearing account with the Escrow Agent, which escrow account is entitled “Tibet Pharmaceuticals, Inc. IPO Escrow Account” (the “Escrow Account”). The
Placement Agent will transfer funds directly to the Escrow Agent as directed by its customers and will instruct other purchasers of the Shares to make checks payable to the Escrow Agent. 

2. Escrow Period. The escrow period (the “Escrow Period”) shall begin with the commencement of the Offering and shall
terminate upon the earlier to occur of the following dates: 
 (a) the date on which the Escrow Agent confirms that it has
received in the Escrow Account gross proceeds of $15,000,000, representing the funds necessary to purchase the Shares (the “Maximum”); 
  (b) December 31, 2010; or 
  (c) the date on which the Placement Agent and the
Company notify the Escrow Agent in writing that the Offering has been terminated. 
 During the Escrow Period, the Company is
aware and understands that it is not entitled to any funds received into escrow and no amounts deposited in the Escrow Account shall become the property of the Company or any other entity, or be subject to the debts of the Company or any other
entity. 
 3. Deposits into the Escrow Account. The Placement Agent agrees that it shall deliver to the Escrow Agent for
deposit in the Escrow Account all monies received from purchasers of the Shares by noon of the next business day after receipt together with a written account of each sale, which account shall set forth, among other things, (i) the
purchaser’s name and address, (ii) the number of Shares purchased by the purchaser, (iii) the amount paid therefor by the purchaser, (iv) whether the consideration received from the purchaser was in the form of a check, draft or
money order, and (v) the purchaser’s social security or tax identification number. The Escrow Agent agrees to hold all monies so deposited in the Escrow Account (the “Escrow Amount”) for the benefit of the parties hereto until
authorized to disburse such monies under the terms of this Agreement. 

 4. Disbursements from the Escrow Account. In the event the Escrow Agent does not
receive minimum deposits totaling $15,000,000 prior to the termination of the Escrow Period, or if the Placement Agent and the Company notify the Escrow Agent that the Offering has been terminated, the Escrow Agent shall promptly refund to each
purchaser the amount received from the purchaser, without deduction, penalty, or expense to the purchaser, and the Escrow Agent shall notify the Company and the Placement Agent of its distribution of the funds. The purchase money returned to each
purchaser shall be free and clear of any and all claims of the Company or any of its creditors. 
 In the event the Escrow Agent
does not receive minimum deposits totaling $15,000,000 prior to termination of the Escrow Period, on the Closing Date (as defined in Section 8), the Escrow Agent shall disburse the Escrow Amount pursuant to the provisions of Section 6,
provided, however, in no event will the Escrow Amount be released to the Company until such amount is received by the Escrow Agent in collected funds. For purposes of this Agreement, the term “collected funds” shall mean all funds,
including fed funds, received by the Escrow Agent which have cleared normal banking channels. 
 5. Collection Procedure.

 (a) The Escrow Agent is hereby authorized to deposit each check in the Escrow Account. 

(b) In the event any check paid by a purchaser and deposited in the Escrow Account shall be returned, the Escrow Agent shall notify the
Placement Agent by telephone of such occurrence and advise it of the name of the purchaser, the amount of the check returned, and any other pertinent information. The Escrow Agent shall then transmit the returned check directly to the purchaser and
shall transmit the statement previously delivered by the Placement Agent relating to such purchase to the Placement Agent. 

(c) If the Company rejects any purchase of Shares for which the Escrow Agent has already collected funds, the Escrow Agent shall promptly
issue a refund check to the rejected purchaser. If the Placement Agent rejects any purchase for which the Escrow Agent has not yet collected funds but has submitted the purchaser’s check for collection, the Escrow Agent shall promptly issue a
check in the amount of the purchaser’s check to the rejected purchaser after the Escrow Agent has cleared such funds. If the Escrow Agent has not yet submitted a rejected purchaser’s check for collection, the Escrow Agent shall promptly
remit the purchaser’s check directly to the purchaser. 
 6. Delivery of Escrow Account. 

(a) Prior to the Closing (as defined in Section 8 of this Agreement), the Placement Agent and the Company shall provide the Escrow
Agent with a statement, executed by each party, containing the following information: 
 (i) The total number of Shares sold by
the Placement Agent directly to purchasers and a list of each purchaser, and the number of Shares purchased by such purchaser, and specification of the manner in which the Shares should be issued; and 

(ii) A calculation by the Placement Agent and the Company as to the manner in which the Escrow Account should be distributed to the
Company and the Placement Agent and in the event of oversubscription or rejection of certain purchasers, the aggregate amount to be returned to individual purchasers and a listing of the exact amount to be returned to each such purchaser.

 The Escrow Agent shall hold the Escrow Account and distribute it in accordance with the above-described statement on the date
of Closing or such later date that it receives the above-described statement. 
 (b) Upon termination of the Offering by the
Company or the Placement Agent for any reason, the Escrow Agent shall return to the purchasers who contributed to the Escrow Account the exact amount contributed by them. 
 7. Investment of Escrow Account. The Escrow Agent shall deposit funds received from purchasers in the Escrow Account, which shall be a non-interest-bearing bank account at SunTrust Bank.

  
 2 

 8. Closing Date. The “Closing” shall be the date of closing of the
Offering, and the “Closing Date” shall be the date on or subsequent to the date on which the Escrow Agent has received minimum deposits of at least $10,002,000 in collected funds that is designated to the Escrow Agent by the Placement
Agent and the Company as the Closing Date. 
 9. Compensation of Escrow Agent. The Company shall pay the Escrow Agent a
fee for its services hereunder in an amount equal to One Thousand Five Hundred Dollars ($1,500), which amount shall be paid on the Closing Date. In the event the Offering is canceled for any reason, the Company shall pay the Escrow Agent its fee
within ten (10) days after the Escrow Amount is refunded to purchasers. No such fee or any other monies whatsoever shall be paid out of or chargeable to the funds on deposit in the Escrow Account. 

10. Disbursement into Court. If, at any time, there shall exist any dispute between the Company, the Placement Agent and/or the
purchasers with respect to the holding or disposition of any portion of the Escrow Amount or any other obligations of the Escrow Agent hereunder, or if at any time the Escrow Agent is unable to determine, to the Escrow Agent’s sole
satisfaction, the proper disposition of any portion of the Escrow Amount or the Escrow Agent’s proper actions with respect to its obligations hereunder, or if the Company and the Placement Agent have not within 30 days of the furnishing by the
Escrow Agent of a notice of resignation appointed a successor Escrow Agent to act hereunder, then the Escrow Agent may, in its sole discretion, take either or both of the following actions: 

(a) suspend the performance of any of its obligations under this Escrow Agreement until such dispute or uncertainty shall be resolved to
the sole satisfaction of the Escrow Agent or until a successor Escrow Agent shall have been appointed (as the case may be); provided, however, that the Escrow Agent shall continue to hold the Escrow Amount in accordance with Section 7
hereof; and/or 
 (b) petition (by means of an interpleader action or any other appropriate method) any court of competent
jurisdiction in Richmond, Virginia, for instructions with respect to such dispute or uncertainty, and pay into court all funds held by it in the Escrow Account for holding and disposition in accordance with the instructions of such court.

 The Escrow Agent shall have no liability to the Company, the Placement Agent or any other person with respect to any such
suspension of performance or disbursement into court, specifically including any liability or claimed liability that may arise, or be alleged to have arisen, out of or as a result of any delay in the disbursement of funds held in the Escrow Account
or any delay in or with respect to any other action required or requested of the Escrow Agent. 
 11. Duties and Rights of
the Escrow Agent. The foregoing agreements and obligations of the Escrow Agent are subject to the following provisions: 

(a) The Escrow Agent’s duties hereunder are limited solely to the safekeeping of the Escrow Account in accordance with the terms of
this Agreement. It is agreed that the duties of the Escrow Agent are only such as herein specifically provided, being purely of a ministerial nature, and the Escrow Agent shall incur no liability whatsoever except for negligence, willful misconduct
or bad faith. 
 (b) The Escrow Agent is authorized to rely on any document believed by the Escrow Agent to be authentic in
making any delivery of the Escrow Account or the certificates representing the Shares. It shall have no responsibility for the genuineness or the validity of any document or any other item deposited with it and it shall be fully protected in acting
in accordance with this Agreement or instructions received. 
 (c) The Company and the Placement Agent hereby waive any suit,
claim, demand or cause of action of any kind which they may have or may assert against the Escrow Agent arising out of or relating to the execution or performance by the Escrow Agent of this Agreement, unless such suit, claim, demand or cause of
action is based upon the gross negligence, willful misconduct, or bad faith of the Escrow Agent. 

  
 3 

 12. Notices. It if further agreed as follows: 

(a) All notices given hereunder will be in writing, served by registered or certified mail, return receipt requested, postage prepaid,
express courier, or by hand-delivery, to the parties at the following addresses: 
 to the Company: 

Tibet Pharmaceuticals, Inc. 
 Room 1701, 17/F 
 90 Jaffe Rd. 

Wanchai, Hong Kong 
 Attention: Taylor Z. Gao, Chief Executive Officer 
  with copy to:

 Kaufman & Canoles, P.C. 
 Three James Center 
 1051 East Cary Street 

12th Floor 
 Richmond, Virginia 23219 
 Attention: Bradley A. Haneberg, Esq. 

to the Placement Agent: 
 Anderson & Strudwick, Incorporated 
 707 East Main
Street, 20th Floor 

Richmond, Virginia 23219 
 Attention: L. McCarthy Downs, III 
 Facsimile: (804) 648-3404 

with copy to: 
 Richard I. Anslow, Esq. 
 Anslow & Jaclin, LLP 

195 Route 9 South, Suite 204 
 Manalapan, NJ 07726 
 Attention: Richard I. Anslow, Esq. 

Facsimile: (732) 577-1188 
 Email: ranslow@anslowlaw.com 
  to the Escrow Agent: 

SunTrust Bank 

919 East Main Street 
 7th Floor

 Richmond, Virginia 23219 
 Attention: Matthew Ward 
 13. Miscellaneous. 

(a) This Agreement shall be binding upon, inure to the benefit of and be enforceable by the parties hereto and their respective successors
and assigns. 
 (b) If any provision of this Agreement shall be held invalid by any court of competent jurisdiction, such
holding shall not invalidate any other provision hereof. 
 (c) This Agreement shall be governed by the applicable laws of the
Commonwealth of Virginia. 
 (d) This Agreement may not be modified except in writing signed by the parties hereto. 

(e) All demands, notices, approvals, consents, requests and other communications hereunder shall be given in the manner provided in this
Agreement. 
 (f) This Agreement may be executed in one or more counterparts, and if executed in more than one counterpart, the
executed counterparts shall together constitute a single instrument. 

  
 4 

 [Tibet Pharmaceuticals, Inc. - Escrow Agreement Execution Page] 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed in their respective names, all as of the date first
above written. 
  

			
	ANDERSON & STRUDWICK, INCORPORATED
		
	By:	 	  

		 	L. McCarthy Downs, III
		 	Managing Director
	
	TIBET PHARMACEUTICALS, INC.
		
	By:	 	  

	Name:	 	Taylor Z. Gao
	Title:	 	Chief Executive Officer
	
	SUNTRUST BANK
		
	By:	 	  

	Name:	 	Matthew Ward
	Title:	 	Assistant Vice President

  
 5Description of Certain Compensatory Arrangements

 Exhibit 10.24 
 Description of Certain Compensatory Arrangements 
 Executive
Compensation 
 Varian Medical Systems, Inc. (the “Company”) does not have a written employment agreement with any
of its named executive officers (determined by reference to the Company’s proxy statement dated December 30, 2009). The annual base salary for calendar year 2011 for each of the Company’s Principal Executive Officer, Principal
Financial Officer, and the other named executive officers will be as follows: 
  

					
	 Name
	  	Base Salary	 
	 Timothy E. Guertin,
Corporate President and Chief Executive Officer
	  	$	924,963	  
	 Elisha W. Finney,
Corporate Senior Vice President, Finance and Chief Financial Officer
	  	$	540,800	  
	 Dow R. Wilson,
Corporate Executive Vice President and President, Oncology Systems
	  	$	630,240	  
	 Robert H. Kluge,
Corporate Senior Vice President and President, X-ray Products
	  	$	424,360	  
	 John W. Kuo,
Corporate Vice President, General Counsel and Corporate Secretary
	  	$	378,290	  

 On November 12,
2010, the Compensation and Management Development Committee (the “Compensation Committee”) set the performance goals for fiscal year 2011 under the Company’s Management Incentive Plan (“MIP”) for the named executive officers
and certain other executives. The annual cash incentives under the MIP for the Company’s Section 16 executives (including the named executive officers) are intended to comply with the exception for performance-based compensation under
Section 162(m) of the Internal Revenue Code. For fiscal year 2011, the Compensation Committee established a pool of funds equal to one and one-quarter percent (1.25%) of the Company’s fiscal year 2011 earnings before interest and
taxes (“EBIT”) results (the “MIP Bonus Pool”) to be available for annual cash incentives under the MIP to this group. The Compensation Committee has discretion to pay each of these executives less than their corresponding share
of the MIP Bonus Pool, which is the lesser of two times the target participation level of each executive under the MIP or a specified percentage of the MIP Bonus Pool (as listed below). Such discretion shall be exercised by the Compensation
Committee based on the achievement of the following performance goals in fiscal year 2011 over fiscal year 2010 and any other factors determined by the Compensation Committee in its sole discretion. In the case of Mr. Guertin,
Ms. Finney and Mr. Kuo, payments under the MIP will be based 40% on EBIT growth for the Company as a whole, 20% on revenue growth for the Company as a whole, 20% on net orders growth for the Company as a whole, and 20% on the
executive’s individual performance relative to specific qualitative goals. In the case of Mr. Wilson, payment under the MIP will be based 20% on EBIT growth for the Company as a whole, 10% on revenue growth for the Company as a whole, 10%
on net orders growth for the Company as a whole, 20% on EBIT growth for the Oncology Systems business segment, 10% on revenue growth for the Oncology Systems business segment, 10% on net orders growth for the Oncology Systems business segment, and
20% on his individual performance relative to specific 

 
qualitative goals. In the case of Mr. Kluge, payment under the MIP will be based 20% on EBIT growth for the Company as a whole, 10% on revenue growth for the Company as a whole, 10% on net
orders growth for the Company as a whole, 20% on EBIT growth for the X-ray Products business segment, 10% on revenue growth for the X-ray Products business segment, 10% on net orders growth for the X-ray Products business segment, and 20% on his
individual performance relative to specific qualitative goals. Payment under the MIP to the named executive officers may vary from $0 to 230% of base salary based upon achievement under the performance goals described above. 

Set forth below are payout levels for each executive if the target and maximum levels under the MIP are achieved: 

 

							
	  	  	Target	  	Maximum (the lesser of
the
following)
	 Name
	  	As a % of
base 
salary	  	As a % of
base 
salary	  	As a % of MIP
Bonus Pool
	 Timothy E. Guertin
	  	115%	  	230%	  	40%
	 Elisha W. Finney
	  	  80%	  	160%	  	16%
	 Dow R. Wilson
	  	  80%	  	160%	  	19%
	 Robert H. Kluge
	  	  65%	  	130%	  	10%
	 John W. Kuo
	  	  60%	  	120%	  	  9%

 These
executive officers have also been extended certain perquisites, such as use of a leased automobile under the Company’s Executive Car Program. Under the Executive Car Program, the Company provides a leased vehicle costing up to $82,000 for the
Chief Executive Officer and leased vehicles costing up to $68,000 for the other named executive officers. Insurance, maintenance expenses and fuel costs are also included in the Executive Car Program. Participants have an option to purchase the car
at the end of its three-year lease period or upon retirement at the lower of its depreciated book value or its fair market value (based on the Kelley Blue Book Auto Market Report wholesale value). 

The Company does not permit its executives to use the Company’s fractionally owned aircraft for purely personal trips. However, the
Company allows and includes in an executive’s compensation, as applicable, aircraft use attributable to permitted spousal use of the fractionally owned aircraft for business purposes and spousal travel on commercial airplanes deemed valuable
and appropriate for business purposes. 
 The Company reimburses executive officers and non-executive officers for financial
planning, estate planning, tax planning, tax return preparation and financial counseling services (to a maximum of $6,500 per year and unlimited for the Chief Executive Officer). The Company also reimburses certain individuals, including all
executive officers and non-executive officers, for annual medical examinations (up to a maximum of $4,000 per year). 

Additionally, for the benefit of the executives, the Company also provides a Company supplemental contribution match representing
retirement contributions which could not be contributed to the executives’ qualified retirement accounts due to Internal Revenue Code limitations. The Company also permits executives to participate in the Company’s Deferred Compensation
Plan, under which they may defer up to 50% of their base salaries and up to 100% of their cash incentives, and in compensation and benefit programs generally available to all other U.S. employees, such as the Company’s Employee Incentive Plan,
Employee Stock Purchase Plan, 401(k) Retirement Program and supplemental life and disability insurance programs. 

 Mr. Wilson’s employment is governed by an offer letter that provides for certain
additional compensation. Please refer to Exhibits 10.22 and 10.23 of the Company’s Annual Report on Form 10-K for the fiscal year ended October 1, 2010. 
 Compensation of Directors 
 Annual Cash Compensation. Each
non-employee director receives an annual retainer of $45,000, except that the lead director receives an annual retainer of $60,000. The chairs of the Compensation Committee and the Nominating and Corporate Governance Committee also receive an
additional $10,000 annual retainer for serving in these positions, and the chair of the Audit Committee receives an additional $15,000. Each non-employee director also receives $2,000 for each Board meeting attended ($1,000 if the Board meeting was
an in-person meeting and the director attended by telephone or video conference), and $1,500 for each committee meeting attended ($750 if the committee meeting was an in-person meeting and the director attended by telephone or video conference).
Directors who are employees receive no compensation for their services as directors. All directors, however, receive reimbursement for out-of-pocket expenses of the directors’ associated with attending Board and committee meetings and for
expenses related to directors’ continuing education programs. Non-employee directors may elect to receive cash compensation as full-value shares of the Company’s common stock, at a value equal to the fair market value of the Company’s
common stock on the date that the foregone cash compensation otherwise would have been paid. Directors may alternatively elect to defer their retainer and/or meeting fees under the Company’s Deferred Compensation Plan, subject to the
restrictions of applicable tax laws. 
 Equity Compensation. New non-employee directors do not receive initial equity
awards, but each continuing non-employee director receives an annual grant of non-qualified stock options to purchase 5,000 shares of common stock at an exercise price equal to the fair market value (i.e., the closing price) of the underlying
shares of the Company’s common stock on the date of grant and an annual grant of Deferred Stock Units having a fair market value on the date of grant of $100,000, based on the fair market value of the Company’s common stock on the date of
grant. 
 Compensation for Levy as a Non-Executive Employee 

In his role as a non-executive employee of the Company (and in addition to his responsibilities as Chairman of the Board), Dr. Levy
provides on-going advice and counsel to the management of the Company on strategic business and technological matters, and has involvement with investor groups and key customers. In connection with this non-executive employee role, Dr. Levy
receives the following compensation: 
  

	 	•	 	 base salary of $160,000; 

  

	 	•	 	 provision of a leased office space at a fair market value; 

 

	 	•	 	 provision of an administrator; and 

  

	 	•	 	 eligibility for the Corporation’s non-executive employee health and welfare benefit plans, subject to his election and contributions towards those
benefit plans, as well as the Employee Incentive Plan. 

 Dr. Levy is not eligible to participate in the
Company’s Management Incentive Plan and in any executive perquisite programs, including the Executive Car Program and reimbursement for executive physicals. He is also not eligible for equity awards, paid personal leave accrual or for any
supplemental retirement contributions in excess of the Company’s matching contributions under the Varian Medical Systems, Inc. Retirement Plan (the Company’s 401(k) Plan). He does not receive any separate compensation for his duties
serving on the Board but receives the same reimbursement of expenses as do all other directors.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}]]